Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | PTGES | O14684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502667 | 0.87 | HSP90AA1 (0.54) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL9501613 | 0.84 | HSP90AA1 (0.53) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL9502701 | 0.82 | HSP90AA1 (0.51) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL9503492 | 0.80 | CYP19A1 (0.62) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL9501952 | 0.80 | CYP19A1 (0.68) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| Ns-398 SCHEMBL214213 | 0.79 | CYP19A1 (1.00) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL9504735 | 0.79 | CYP19A1 (0.61) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL9504767 | 0.79 | CYP19A1 (1.00) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| Ns-398 SCHEMBL29368077 | 0.79 | CYP19A1 (1.00) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 | |
| Ns-398 SCHEMBL9505669 | 0.78 | CYP19A1 (0.98) | CYP19A1MAPTSMN1; SMN2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1689382-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND AN AGENT INTERVENING IN THE PROSTAGLANDIN METABOLISM | Boehringer Ingelheim International GmbH (DE) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005060955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND AN AGENT INTERVENING IN THE PROSTAGLANDIN METABOLISM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-07 | — | — | WO | disclosed |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1476146-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1467765-A2 | COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1463500-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040152752-A1 | Treatment for human papillomavirus | PHARMACIA & UPJOHN COMPANY | 2004-08-05 | — | — | US | disclosed |
| WO-2003101438-A1 | TREATMENT FOR HUMAN PAPILLOMAVIRUS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030211163-A1 | Combination antiviral therapy | PHARMACIA & UPJOHN COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-20030191051-A1 | Combination therapy for the treatment of bacterial infections | PHARMACIA & UPJOHN COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | VERSI EBRAHIM (US) | 2003-10-09 | — | — | US | disclosed |
| WO-2003070233-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003061704-A2 | COMBINATION THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1282423-A2 | PREVENTION OF INSULIN-DEPENDENT DIABETES, COMPLICATIONS THEREOF, OR ALLOGRAFT REJECTION BY INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY WITH NS398 OR PDTC | Oklahoma Medical Research Foundation (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20030017148-A1 | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2003-01-23 | — | — | US | disclosed |
| WO-2001085175-A2 | PREVENTION OF INSULIN-DEPENDENT DIABETES, COMPLICATIONS THEREOF, OR ALLOGRAFT REJECTION BY INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY WITH NS398 OR PDTC | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211163-A1 | Combination antiviral therapy | EIF2AK2, ZC3HAV1, VHL | CYP19A1 3705/4885MAPT 4530/4885SMN1; SMN2 4289/4885 |
| US-20050119239-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism | ADRB3, ADRB2, ADRB1 | CYP19A1 855/4885MAPT 2900/4885SMN1; SMN2 2211/4885 |
| US-20030191051-A1 | Combination therapy for the treatment of bacterial infections | PTGS1, PTGES, PTGES3 | CYP19A1 2386/4885MAPT 4458/4885SMN1; SMN2 4674/4885 |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | PTGS2, PTGES2, PTGS1 | CYP19A1 624/4885MAPT 3765/4885SMN1; SMN2 2398/4885 |
| US-20040152752-A1 | Treatment for human papillomavirus | TP53, POLI, VHL | CYP19A1 1808/4885MAPT 2643/4885SMN1; SMN2 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.